Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Alzamend Neuro Inc (ALZN)

Alzamend Neuro Inc (ALZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 113,624
  • Shares Outstanding, K 95,482
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,360 K
  • 60-Month Beta -0.15
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.96
Trade ALZN with:

Options Overview Details

View History
  • Implied Volatility 366.20% ( +115.15%)
  • Historical Volatility 68.10%
  • IV Percentile 90%
  • IV Rank 38.03%
  • IV High 775.74% on 05/24/22
  • IV Low 114.84% on 10/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3,751
  • Volume Avg (30-Day) 1,483
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 17,151
  • Open Int (30-Day) 7,232

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 07/31/22
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.03
  • Growth Rate Est. (year over year) -133.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8561 +19.14%
on 07/26/22
1.2800 -20.31%
on 08/17/22
+0.0900 (+9.68%)
since 07/19/22
3-Month
0.8101 +25.91%
on 06/16/22
1.2800 -20.31%
on 08/17/22
+0.1096 (+12.04%)
since 05/19/22
52-Week
0.8005 +27.42%
on 05/12/22
3.5700 -71.43%
on 09/30/21
-2.3200 (-69.46%)
since 08/19/21

Most Recent Stories

More News
Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL001 Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”),...

ALZN : 1.0200 (-14.29%)
Alzamend Neuro to Present at the 12th Annual LD Micro Invitational

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)
Alzamend Neuro Announces Pre-IND Submission for AL001 as a Treatment of Bipolar Disorder, Major Depressive Disorder and Post-Traumatic Stress Disorder

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)
Alzamend Neuro Announces Initiation of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”) announced today its wholly owned subsidiary, Digital Power Lending, LLC (“ DP Lending...

NILE : 0.3150 (-0.79%)
ALZN : 1.0200 (-14.29%)
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ” or the “ Company ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative...

ALZN : 1.0200 (-14.29%)
NILE : 0.3150 (-0.79%)
BitNile Holdings Reports 2021 Year-End Results

BitNile Holdings, Inc. (NYSE American: NILE), a diversified holding company (“ BitNile ” or the “ Company ”) today announced its financial results for the year ended December 31, 2021 contained...

NILE : 0.3150 (-0.79%)
ALZN : 1.0200 (-14.29%)
Alzamend Neuro Contracts with Altasciences and iResearch Atlanta to Manage and Conduct Its Phase IIA Study in Patients with Alzheimer’s

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)
Alzamend Neuro Appoints Dr. Terri Hunter to Its Scientific Advisory Board

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)
Alzamend Neuro Announces Full Data Set From Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric...

ALZN : 1.0200 (-14.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Alzamed Neuro is an early clinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Their mission is to rapidly develop and market safe and effective treatments. Their current pipeline...

See More

Key Turning Points

3rd Resistance Point 1.2867
2nd Resistance Point 1.2333
1st Resistance Point 1.1267
Last Price 1.0200
1st Support Level 0.9667
2nd Support Level 0.9133
3rd Support Level 0.8067

See More

52-Week High 3.5700
Fibonacci 61.8% 2.5121
Fibonacci 50% 2.1853
Fibonacci 38.2% 1.8584
Last Price 1.0200
52-Week Low 0.8005

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar